Targeted News Service

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjogren's disease that reveal insights on importance of symptom improvements most valued by patients
November 07, 2026

RARITAN, New Jersey, Nov. 7 [Category: BizPharmaceuticals] -- Johnson and Johnson Innovative Medicine posted the following news release:

* * *

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjogren's disease that reveal insights on importance of symptom improvements most valued by patients

*

New Brunswick, NJ. (November 7, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form